When it comes to prostate cancer imaging, accurate detection lies in the details.\textsuperscript{1} And you can't treat what you can't detect. Using optimal technology, targets, tracers, and tools such as \textbf{PET}, \textbf{PSMA}, \textsuperscript{18}F, and \textbf{AI systems} could improve diagnostic performance and help pave the way for more informed prostate cancer treatment decisions.\textsuperscript{1-5}

\textbf{We are investigating ways to take imaging to the next level. Learn how at FoursightProstateCancer.com}

Virtual Presentation.
Real-World Results.

SNMMI and ACNM are excited to welcome you virtually to the 2021 SNMMI Mid-Winter and ACNM Annual Meeting.

Over 3.5 days, you'll experience a virtual platform that incorporates both the intimate format and collaborative environment you've come to expect from the meeting, with a dynamic, virtual attendee experience that (almost) makes you forget you're not meeting in person!

The meeting will feature three educational tracks highlighting the latest innovations and techniques in the field. Scientific sessions, industry-led satellite symposiums, and technologist-focused programming are also available, providing you with a comprehensive learning opportunity!

Best of all, since the meeting is being held virtually, you have the flexibility to experience the entire meeting from the comfort and safety of your home or office, when it's convenient for you.

The 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting lets you:

- Watch Sessions When/Where it’s Convenient for You
  - Watch sessions live as they happen. The sessions will feature live chat functionality during live broadcasts of the presentations. Miss a session? Each session will be available for on-demand viewing following its live broadcast for 30 days. Plus, as a registered attendee, you’ll get access to additional technologist-focused programming taking place February 2-6.

- View Leading Research in Dedicated Science Pavilion
  - View abstract presentations and posters of the profession's latest research, including recorded oral presentations from the authors. You will also be able to ask the authors questions by emailing them while visiting their poster/abstract.

- Interact with Industry Suppliers in the Virtual Exhibit Hall
  - Visit 30 customized virtual booths from top suppliers and learn more about their products/services through videos and downloadable presentations. Plus, connect one-on-one with exhibit personnel while visiting their booth through direct text and video chat.

- Re-Connect with Colleagues and Luminaries during Innovative Networking Opportunities
  - Interact with fellow attendees through one-on-one and group chat, and during great networking events, highlighted by the ACNM Awards Ceremony. During this marquee event, ACNM will honor its 2021 Lifetime Achievement Award Winner; 2021 Gold Medal Award winner; present the ACNM Abstract Awards; and induct its 2021 Class of Fellows.

THANK YOU TO OUR TITLE SPONSOR

We would like to recognize our title sponsor, Advanced Accelerator Applications, a Novartis Company, for their generous support of the 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting.

Earn up to 27.5 continuing education credits.
On behalf of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Scientific Program Committee, I would like to welcome you to the Virtual 2021 SNMMI Mid-Winter and ACNM Annual Meeting.

As we continue to navigate this unprecedented time, I would like to sincerely thank the many planners of this year’s meeting – the SNMMI Scientific Program Committee, SNMMI’s Councils and Centers of Excellence, the SNMMI Technologist Section, and the American College of Nuclear Medicine (ACNM). Despite all the personal and professional challenges that everyone is facing, they have once again collaborated to plan a truly exceptional meeting.

This year our focused track will be on therapy. This track will showcase both cutting-edge research and development in this area as well as the practical clinical application of therapies. This content will cover the latest on therapies for prostate cancer, NETs, thyroid, and pediatric patients. We would like to thank the Therapy Center of Excellence for their many efforts in planning this informative track.

There will also be a General Nuclear Medicine Track offering a variety of timely topics:

- Investing in Inclusion: Why and How
- Hot Topics in Nuclear Cardiology 2020: Case Based Review
- COVID-19: Effects on Clinical Care and Education
- Artificial Intelligence in Nuclear Medicine
- Molecular Brain Imaging and the ATN Framework
- Pediatric Nuclear Medicine Applications: Common to Obscure

In addition to the content offered over the 3.5 days of the meeting, participants will be able to attend exclusive supplemental content in the days following the meeting. There will be a week of content planned by the Technologist Section as well as additional General Nuclear Medicine Track sessions. If you are registered for the Mid-Winter Meeting, you will automatically be registered for these supplemental sessions in February and March.

This year’s meeting will also offer six educational Satellite Symposia delivered by our industry partners. I would encourage you to participate in these informative sessions. I would also like to sincerely thank this year’s exhibitors and sponsors for their contributions to making this meeting a success. Make sure you take the time to visit the Exhibit Hall. Industry representatives will be in the Exhibit Hall throughout the meeting to showcase their latest offerings and answer your questions.

And finally, there will be several networking opportunities in the evenings that you won’t want to miss. While we can’t be together in person, we can still enjoy a sense of community through these virtual networking events.

We hope you enjoy the meeting!

Best wishes,

Umar Mahmood, MD, PhD
Chair, SNMMI Scientific Program Committee
It is our pleasure to welcome you to the “COVID free” 2021 ACNM Virtual Annual Meeting held in conjunction with the SNMMI Mid-Winter Meeting. This year, we are bringing the “The Latest and Greatest of Nuclear Medicine” to your private screens.

The ACNM is proud to showcase the research of young professionals. The ACNM Research Abstract Oral Presentations will be held on Thursday afternoon. Please log in and support the future of our profession. This year we are extending the award categories to recognize physics and new technological innovations’ abstracts. Selected virtual presentations will be nominated and awarded by a panel of judges. The winners will be announced in the virtual ACNM Awards Ceremony and Banquet on Friday night.

The ACNM 2020 President, Dr. Yang Lu, will open the educational program on Friday morning, followed by expert panel sessions of “The latest and greatest ” theranostics, development, clinical use of Breast PET FES, and the impact of genetics on thyroid cancer management. For the recognition of women in nuclear medicine, we have invited women nuclear medicine physicians to discuss the clinical outcome of PRRT for neuroendocrine tumors in the Asian population, the change in the imaging paradigm in prostate cancer in India, and the theranostic use of radionanomedicine in South Korea. The day will be concluded with a case-based SAM session discussing the topics presented throughout the day. In this meeting, we will offer both CME and SAM credits.

This year the Mandell-Alavi Plenary lecture session will take place on Friday from 11:45 am-1:15 pm ET. The plenary lecture, generously endowed by Drs. Gerald Mandell and Abass Alavi, supports a keynote speaker who has had an extraordinary influence on the advancement of nuclear medicine. This year with great honor, the Mandell-Alavi Plenary lecture will be given by Dr. John A. Katzenellenbogen from the University of Illinois. Dr. Katzenellenbogen is recognized for contributing to the development of novel hormone-regulated PET imaging agents 18F-Estrogen (FES) receptors in breast cancers and 18F-androgen (FDHT) receptors in prostate cancers.

The annual ACNM Awards Ceremony will be held virtually. As every year, we are honored to invite you for a social evening of networking and with colleagues. At the banquet, we will announce ACNM’s annual awards, including the 2021 ACNM Fellows’ election and the recognition of this year’s Gold Medal, Lifetime Achievement, Best Mentor, and Abstract Awards. In addition, we are excited to announce an international recital performance for our talent show; the singer Eva (Xiaohua) Zhu and Vivian (Boxianzi) Ling, a violinist from the San Francisco Symphony. In addition, members of ACNM’s leadership team, Dr. Twyla Bartel and Dr. Tracy Yarbrough will take the virtual stage for a duet. And as an added treat for the evening, we are delighted to have Brennan Ayres, the son of Dr. Karen Ayres, entertain us with a special piano solo.

We are excited to see you at our annual meeting virtually. If you are not already, we hope you will join us as an ACNM member.

Sincerely,
ACNM Program Committee
Bital Savir-Baruch, MD, Chair of the 2021 ACNM Program Committee
Mariam Aboian, MD, Ph.D.
Alan Klitzke, MD, Ph.D. FACNM
Bruce Barron, MD, FACNM
Twyla Bartel, DO, MBA, FACNM
Simin Dadparvar, MD, FACNM, FACR
Gary Ulaner, MD, Ph.D., FACNM
Yang Lu, MD, Ph.D., FACNM
Sean Xuexian Yan, MD

WELCOME MESSAGE
FROM THE ACNM PROGRAM COMMITTEE
ORAL Presentations
Thursday, January 28, 2021
2:30-4:30 pm (Oral Session #1)

Oral Presentations will be given in the order below.
Each presentation will be 8 minutes with 2 minutes for questions.

**Oral Session #1**

**Golmehr Sistani**
The Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy in the Treatment of Various Types of Neuroendocrine Tumours with Variable Dose: Phase II Registry Study (oral #1)

**Ida Sonni**
Head-to-Head comparison of 68Ga-PSMA-11 PET/CT and MP-MRI in the Detection, Intra-Prostatic Localization and Local Extension of Primary Prostate Cancer: A Single-Center Imaging Study with Histopathology Gold-Standard (oral #2)

**Ashanth Thomas**
Every Breath Counts: A Novel Application of Quantitative Lung with SPECT/CT to Evaluate the Efficacy of BLVR (oral #3)

**Syed Bukhari**
Development and Validation of a Diagnostic Model and Clinical Score to Predict a Positive Tc-99m Pyrophosphate Scintigraphy: A Pilot Study (oral #4)

**Ashwin Parihar**
68Ga-Dota-Exendin PET/CT versus Contrast Enhanced Computed Tomography in Patients with Hyperinsulinemic Hypoglycaemia (oral #5)

**Reyhaneh Manafi-Farid**
Five-year Biochemical Recurrence-Free Survival Following Radionuclide-Guided Super-Extended Versus Standard Extended Pelvic Lymphadenectomy in Patients with Clinically Localized Prostate Cancer (oral #6)

**David Cardoza-Ochoa**
Frequency of Pitfalls and Detection Efficacy of 18F-PSMA-1007 PET/CT in Patients with Biochemically recurrent Prostate Cancer (oral #7)

**Sara Pacella**
Predictive Role of 18F-FDG PET/CT in Alzheimer’s Disease (oral #8)

**Oral Session #1**

**Susan Shafiei**
Different Dose Strategies for Radioiodine Therapy of Patients with Graves’ disease, A Clinical Trial (oral #9)

**Sara Shakeri**
Evaluation of the Role of 68Ga-PSMA PET/CT Scanning in Patients with High Risk Prostate Cancer (oral #10)

**Sonya Youngju Park**
Pilot Study Evaluating the Role of Novel PSMA Ligand 18F-Florastamin PET/CT in Men with Clinical Suspicion of Prostate Cancer (oral #11)

**Reyhaneh Manafi-Farid**
Prognostic Value of 18F FDG PET-CT in Metastatic Melanoma Patients Receiving Immunotherapy (oral #12)
**ORAL Presentations**

**Thursday, January 28, 2021**

4:45-6:45pm (Oral Session #2)

Oral Presentations will be given in the order below.
Each presentation will be 8 minutes with 2 minutes for questions.

**Oral Session #2**

**TMengshi Li**

Pb-212 α-Particle Radiotherapy Induces Immunogenic Cell Death and Synergistic anti-Tumor Effect in Combination with Immunotherapies
*(oral #1)*

**Najme Karamzade-Ziarati**

Impact of TSH Stimulation on 18F FDG PET/CT Results in Patients with Papillary Thyroid Carcinoma Presented with Elevated Serum Thyroglobulin Level and Negative Diagnostic 131I Whole-Body Scan
*(oral #2)*

**Heying Duan**

Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma from a Single Institution Experience
*(oral #3)*

**Maithaa El-Dakhely**

The Relation between Bone Marrow Uptake in Baseline 18F-FDG-PET/CT and Bone Marrow Biopsy in Patients with Diffuse Large B Cell Lymphoma
*(oral #4)*

**Jad El Bulbul**

Ongoing Androgen Deprivation Therapy in Patients with Biochemical Recurrent Prostate Cancer Does Not Influence the Positivity Rate of 18F-Fluciclovine PET/CT Scan
*(oral #5)*

**Jad El Bulbul**

Positivity Rate of 18F-Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence and Low PSA Values of < 1 ng/mL
*(oral #6)*

**Damian Grybowski**

The Role of 18F-Fluciclovine PET/CT Scan in the Identification of Patients with Oligometastatic Prostate Cancer
*(oral #7)*

**Edgar Zamora**

*(oral #8)*

**Arun Kumar**

Experience with a Perfusion-Only Screening Protocol for Evaluation of Pulmonary Embolism During the COVID-19 Pandemic Surge
*(oral #9)*

**Patrick Earl Fernando**

A Comparative Study of Different Methods of Estimating Glomerular Filtration Rate in a Subset of Filipinos with Normal Renal Function
*(oral #10)*

**Heying Duan**

Peptide Receptor Radionuclide Therapy (PRRT) in Non-Midgut Neuroendocrine Tumors (NETs) from a Single Institution Experience
*(oral #11)*

**Nicholas DiSanti**

99MTC-MAA SPECT/CT Measuring Reperfusion Following Acute Pulmonary Embolism: Is Anticoagulation Superior to Reperfusion Therapy
*(oral #12)*
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Abstract Title</th>
<th>Presenting Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Exercise Myocardial Perfusion Imaging And Transient Ischemic Dilation: An Angiographic Correlative Study</td>
<td>Besher Sadat</td>
</tr>
<tr>
<td>2</td>
<td>Efficacy, Safety and Prognostic Factors Affecting Overall Survival among Metastatic Prostate Cancer Patients Undergoing Treatment with $^{177}$Lu-PSMA-617: A Single Center Study from Iran</td>
<td>Soroush Zarehparvar</td>
</tr>
<tr>
<td>3</td>
<td>Quantitative Assessment of Asphericity as a New Predictor of Adverse Outcome in Patients with Neuroblastoma</td>
<td>Mikhail Yadgarov</td>
</tr>
<tr>
<td>4</td>
<td>Characterization of Radioactive Citrate Uptake in Hepatocellular Carcinoma</td>
<td>Seon Yoo Kim</td>
</tr>
<tr>
<td>5</td>
<td>Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing I-123 Ioflupane SPECT/CT Imaging</td>
<td>Jeanne Vu</td>
</tr>
<tr>
<td>6</td>
<td>Correlation of Pre-Operative Sonographic Tumor Size with Pathologic Findings in Patients with Thyroid Carcinoma</td>
<td>Somaye Barashki</td>
</tr>
<tr>
<td>7</td>
<td>A Novel Method for Accurate Quantification of Split Glomerular Filtration Rate Using Combination of 99mTc-DTPA SPECT and its Plasma Clearance</td>
<td>Xiaoxi Pang</td>
</tr>
<tr>
<td>8</td>
<td>Oncologic Significance of Incidental Osseous Foci on FDG-PET Without Correlative CT Abnormalities</td>
<td>Edgar Zamora</td>
</tr>
<tr>
<td>9</td>
<td>68GA-Dotatate PET/CT Referrals for Elevated Chromogranin-A</td>
<td>Edgar Zamora</td>
</tr>
<tr>
<td>10</td>
<td>Repeat Injection Following Sentinel Node Non-Visualization on Lymphoscintigraphy Images Can Decrease Axillary Dissection Rate in Breast Cancer Patients</td>
<td>Atena Aghaee</td>
</tr>
<tr>
<td>11</td>
<td>Prognostication of Bone Marrow Uptake in Baseline 18F-FDG-PET/CT in Diffuse Large B Cell Lymphoma Patients</td>
<td>Maithaa El-Dakhely</td>
</tr>
<tr>
<td>12</td>
<td>Diagnostic Performance of Clinical 18F-Fluciclovine PET/CT Scan in Recurrent Prostate Cancer</td>
<td>Damian J. Grybowski</td>
</tr>
<tr>
<td>13</td>
<td>Comparison of Half-Time Oatmeal Gastric Emptying Using Linear and Exponential Curves In Symptomatic Patients</td>
<td>Gbenga A. Shogbesan</td>
</tr>
<tr>
<td>14</td>
<td>Low dose $^{18}$F- FDG PET/CT Brain Scan Versus Standard Dose in Patients with Dementia</td>
<td>Merzia Subhan</td>
</tr>
<tr>
<td>15</td>
<td>A Novel Approach Using FDG PET/CT Based Radiomics to Assess tumor Immune Phenotytpesin Patients with Non-Small Cell Lung Cancer</td>
<td>Jianyuan Zhou</td>
</tr>
<tr>
<td>16</td>
<td>Diagnostic role of $^{18}$F FDG PET/CT in Differentiating Pericardial Benign and Malignant Disease</td>
<td>Rang Wang</td>
</tr>
<tr>
<td>17</td>
<td>Gallium 68 DOTANOC in Neuroendocrine Tumors: An Institutional Review</td>
<td>Tehreem Zafar</td>
</tr>
<tr>
<td>18</td>
<td>Rate of Reported Orbital Metastases from Neuroendocrine Tumors During 68Gallium-DOTANOC PET/CT Imaging</td>
<td>Ethan Y. Lin</td>
</tr>
<tr>
<td>19</td>
<td>Imaging Yttrium 90 Utilizing 3d Time of Flight PET/CT Following Trans Arterial Radioembolization: Overcoming Low Quality Bremsstrahlung Images.</td>
<td>Harkanwar Gill</td>
</tr>
<tr>
<td>20</td>
<td>An Evaluation of Nuclear Radiology Fellowship Websites in the United States</td>
<td>Tushar Garg</td>
</tr>
<tr>
<td>21</td>
<td>Noise-Signal Trade-Off In Maximum Likelihood Estimation</td>
<td>Dacian V. Bonta</td>
</tr>
<tr>
<td>22</td>
<td>Attr Amyloidosis</td>
<td>Kush Shah</td>
</tr>
<tr>
<td>23</td>
<td>Tc99m-Octerotate Scan in Differentiated Thyroid Cancer Patients with Negative Whole Body Iodine Scan, a Low Cost but Relatively Effective Method</td>
<td>Atena Aghaee</td>
</tr>
<tr>
<td>24</td>
<td>Incidental Findings on Tc99m Labelled Radionuclide Renal Scans and to Highlight the Utility of Flow Images</td>
<td>Jitesh Dhirga</td>
</tr>
<tr>
<td>25</td>
<td>Lutathera Spill: Are We Prepared on What Happens Then and What Happens Next!!</td>
<td>Jitesh Dhirga</td>
</tr>
<tr>
<td>26</td>
<td>Usage of Non-Negative Matrix Factorization in the Differentiation of Invasive and Normal Breast Tissue in Mice</td>
<td>Valerie Kobzarenko</td>
</tr>
<tr>
<td>27</td>
<td>F18 FDG PET-CT in Hepatocellular Carcinoma: Institutional Experience from Pakistan</td>
<td>Myda Muzaffar</td>
</tr>
<tr>
<td>28</td>
<td>Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy with $^{177}$LuLu-PSMA in Metastatic Castrate-Resistant Prostate Cancer: A Review</td>
<td>Reyhaneh Manafi-Farid</td>
</tr>
<tr>
<td>29</td>
<td>Nuclear Medicine Practice During COVID-19 Pandemic in Japan</td>
<td>Asami KITAOKA</td>
</tr>
<tr>
<td>30</td>
<td>Brain ECD-SPECT/CT: Transient Antiphospholipid Stroke-Like Presentation of COVID-19</td>
<td>Kwang J. Chun</td>
</tr>
</tbody>
</table>
ACNM AWARD WINNERS

2021 Gold Medal Award
The ACNM Gold Medal recognizes individuals who have made exceptional contributions to the field of nuclear medicine and molecular imaging. The 2020 winner is: Jay Harold, MD, FSNMMI

2021 Lifetime Achievement Award
Each year, the ACNM presents the Lifetime Achievement Award to an individual who has demonstrated an outstanding level of dedication to the ACNM and the field of Nuclear Medicine. The 2020 winner is: Twyla Bartel, DO, MBA, FACNM

2021 ACNM Fellows
Fellowship status in ACNM is awarded for recognition of significant and sustained service to the college and to the nuclear medicine community. It is with great honor that we acknowledge the following individuals as the 2019 ACNM Fellows:

- Carina Aparici, MD
- Karen Ayres, MD
- Joseph Osborne, MD, PhD
- Jing Wang, MD, PhD
- Xiaohua Zhu, MD, PhD
- Katherine Zukotynski, MD, PhD, FRCPC, PEng

*ACNM Personal Best Mentor
The Personal Best Mentor is reserved for those who selflessly devote their time with amiability, demeanor, and dedication to mentoring nuclear medicine professionals for leading a productive personal and professional life. The winner of the 2021 Personal Mentor-of-the-Year is: Somali Gavane, MD

*These ACNM grants are made possible through a gift to the Education and Research Foundation for Nuclear Medicine and Molecular Imaging’s ACNM Fund.

ACNM Clinical Best Mentor
The Clinical Best Mentor reserved for those dedicated teachers of nuclear medicine in the most general term (including teachers of clinical and scientific basis of NM to trainees, other colleagues and the field at large). The winner of the 2021 Clinical Best Mentor-of-the-Year is: Shahram Bonyadlou, MD

*These ACNM grants are made possible through a gift to the Education and Research Foundation for Nuclear Medicine and Molecular Imaging’s ACNM Fund.
ACNM President’s Awards

ACNM President’s awards are awarded to members, fellows and staff of the college who have contributed selflessly to advance the mission of the college and the field of nuclear medicine during 2020 and helped the President of the college during the year. The ACNM President’s awards are given to:

- Mariam Aboian, MD, PhD
- Twyla Bartel, DO, MBA, FACNM
- Somali Gavane, MD
- Ben Greenspan, MD, FACNM, FACR, FSNMMI
- Virginia Pappas
- Warren Janowitz, MD, JD
- Bital Savir-Baruch, MD
- Richard Wahl, MD, FACNM
- Nikki Wenzel-Lamb
- Franklin Wong, MD, PhD, JD
- Babak Saboury, MD, MPH, DABR, DABNM

ACNM Editorial Fellowship Award

Sara Sheikhbahei, MD, MPH is awarded the 2021 ACNM Editorial Fellowship. The ACNM Editorial Fellowship includes a $1,000 award and is designed to provide, a young professional in nuclear medicine, with 12 months of first-hand experience with scholarly publication and editorial processes. Dr. Sheikhbahei will spend a year under the guidance of the current Editor-in-Chief of Clinical Nuclear Medicine and will also have the opportunity to work directly with the editors of Scanner and Scintillator.

The award is funded by a temporarily Restricted Gift Agreement by Patrick M. Colletti, MD, FACNM, FSNMMI for the American College of Nuclear Medicine through the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF).

2021 Mandell-Alavi Lectureship on Advances in Molecular Imaging

Dr. John Katzenellenbogen, Swanlund Professor of Chemistry, directs a vigorous research program that spans chemistry, biology, and medical applications with a particular focus on the action of estrogens in breast cancer and androgens in prostate cancer. He is recognized internationally as pioneer in the development of novel diagnostic and therapeutic agents for the management of hormone-regulated cancers, including the PET imaging agents FES for estrogen receptors and FFNP for progesterone receptors in breast cancers, and FDHT for androgen receptor in prostate cancers that are widely used in the staging of disease and in the clinical development of novel anti-hormones. He has also assisted in the development of a PET-based hormone challenge test that images hormone-induced changes in tumor metabolism and other molecular targets that is proving highly predictive of response to endocrine therapies in breast cancer. Through his extensive work elucidating the molecular details of estrogen action in various target tissues, he has designed novel estrogens that are being actively used to elucidate estrogen actions by numerous collaborators throughout the world. He has been honored as a Member of the American Academy of Arts and Sciences and is the recipient of numerous awards from the American Chemical Society, the Endocrine Society, the Society for Nuclear Medicine, and the International Society for Radiopharmaceutical Sciences.
ACNM ANNUAL MEETING TRACK – “THE LATEST & GREATEST”

The ACNM 2021 Annual Meeting track will feature a robust program of cutting-edge educational content and oral presentations, highlighted by John A. Katzenellenbogen, PhD, who will present the Mandell-Alavi Plenary Session. In addition, all meeting attendees are invited to attend ACNM Awards Ceremony and Banquet on Friday evening. During this event the ACNM will honor its 2021 ACNM Lifetime Achievement Award Winner, 2021 Gold Medal Award winner, present the ACNM Abstract Awards; and induct its 2021 Class of Fellows.

Thursday, January 28

2:00–2:30 pm ET

Opening/Welcome Session

2:30–4:30 pm ET

ACNM Oral Abstract Presentations

4:45–6:45 pm ET

ACNM Oral Abstract Presentations

Friday, January 29

10:00–11:30 am ET

ACNM’s President’s Session

Sponsored by the ACNM

Organizer: Yang Lu, MD, PhD, FACNM
Moderator: Yang Lu, MD, PhD, FACNM

Session Description
This session will focus on the up-to-date research and current clinical practice of nuclear medicine.

Session Objectives
1. Discuss ACNM’s efforts and initiatives in 2020; ACNM’s vision and resolution for the years to come
2. Describe the perspectives of nuclear medicine leaders about the future of nuclear medicine, joined by live discussions
3. Examine the newly FDA approved FES PET tracer, and its impact on nuclear medicine practices

Presentations Include:
- ACNM in the Era of Theranostics: Stay Current and Keep Advancing
  Yang Lu, MD, PhD, FACNM
- Nuclear Medicine and Molecular Imaging in the Last Two Decades: Lessons Learned and Future Directions
  Rathan Subramaniam, MD, PhD, MPH, FACNM, FSNMMI
- PET Imaging of Estrogen Receptors in Breast Cancer
  David A. Mankoff, MD, PhD

Friday, January 29

11:45 am–1:15 pm ET

Mandell-Alavi Award Session

Sponsored by the ACNM

Organizer: Gary Ulaner, MD, PhD, FACNM; Bital Savir-Baruch, MD
Moderator: Gary Ulaner, MD, PhD, FACNM

Session Description
This session introduces the newly approved FES PET/CT tracer in the imaging of breast cancer.

Session Objectives
1. Participate in the introduction of [18]F-fluoroestradiol
2. Discuss the clinical use of [18]F-fluoroestradiol
3. Describe the [18]F-fluoroestradiol effect on clinical management

Presentations Include:
- Introduction of FES PET/CT
  Farrokh Dehdashti, MD
- The Mandell-Alavi Award Lectureship: FES and FFNP PET Imaging in Breast Cancer: A Single Goal in an Ever-changing Landscape
  John A. Katzenellenbogen, PhD
- Q&A
**ACNM ANNUAL MEETING TRACK – “THE LATEST & GREATEST”**

**Friday, January 29**

2:15–3:45 pm ET  
**Operationalizing Genetic and Molecular Characterization in the Management of Differentiated Thyroid Cancer**  
*Sponsored by the ACNM*

Organizer: Mark Tulchinsky, MD, FACNM, FSNMMI  
Moderator: Alan Klitzke, MD, Ph.D. FACNM

**Session Description**  
This session will discuss the importance of genetic mutations and thyroid cancer treatment.

**Session Objectives**  
1. Discuss common practice with thyroid cancer management  
2. Examine the importance of genetic mutation in the management of thyroid cancer  
3. Describe targeted therapy of differentiator thyroid cancer

**Presentations Include:**  
- Genomic and Molecular Principles of Theranostic Surgical Management of Differentiated Thyroid Cancer  
  *Seza A. Gulec, MD, FACS, FACNM*  
- Integration of Genetic Mutations into Theranostic Nuclear Medicine  
  *Mark Tulchinsky, MD, FACNM, FSNMMI*  
- Targeted Therapy in Thyroid Cancer: Reversal of Fortune  
  *Seza A. Gulec, MD, FACS, FACNM*  
- Metabolic and Molecular Characterization of Differentiated Thyroid Cancer for Thera-Nuclear Management  
  *Mark Tulchinsky, MD, FACNM, FSNMMI*

**Friday, January 29**

4:14–5:45 pm ET  
**ACNM International Session: The Latest and Greatest Around the Globe**  
*Sponsored by the ACNM*

Organizer: Twyla B. Bartel, DO, MBA, FACNM  
Moderator: Twyla B. Bartel, DO, MBA, FACNM

**Session Description**  
This year, the ACNM would like to reaffirm its support of women in science in the annual international session. Presented will be a few topics of the latest use of nuclear medicine in their respective countries. The intended audience is for all nuclear medicine specialists.

**Session Objectives**  
1. Share the experience of treating patients with peptide receptor radionuclide therapy in an Asian population  
2. Demonstrate how Ga68 PSMA imaging is an invaluable tool to investigate the biological behavior of prostate cancer  
3. Gain insights into the theranostic use of radionanomedicine

**Presentations Include:**  
- Clinical Outcome of PRRT for Neuroendocrine Tumors in Asian Population  
  *Dr. Wei Ying Tham*  
- Ga68 PSMA: Changing the Imaging Paradigm in Prostate Cancer  
  *Dr. Ishita Sen*  
- Theranostic Use of Radionanomedicine  
  *Dr. So Won Oh*

**Friday, January 29**

6:00–7:30 pm ET  
**Case-Based Summary and Review, Read with the Experts**  
*Sponsored by the ACNM*

Organizer: Bital Savir-Baruch, MD; Tracy L. Yarbrough, MD, PhD, MAEd, FACNM; Twyla B. Bartel, DO, MBA, FACNM  
Moderator: Bital Savir-Baruch, MD; Tracy L. Yarbrough, MD, PhD, MAEd, FACNM; Twyla B. Bartel, DO, MBA, FACNM

**Session Description**  
In this session, the speakers will present SAM formatted collection of questions written by different nuclear medicine experts.

**Session Objectives**  
1. Describe the clinical use of $^{18}$F-fluorodeoxyglucose, $^{11}$C-fluciclovine, $^{68}$Ga-DOTA-TATE radiopharmaceuticals.  
2. Discuss the clinical approach to theranostics with highlight to lutetium Lu 177 dotatate and I131.  

**Presentations Include:**  
- Case-Based Summary and Review, Read with the Experts  
  *Bital Savir-Baruch, MD; Tracy L. Yarbrough, MD, PhD, MAEd, FACNM; Twyla B. Bartel, DO, MBA, FACNM*

**Q&A**
The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

**SATURDAY, JANUARY 30**

10:00–11:30 am ET

The Nuts and Bolts of IV Radiopharmaceutical Therapy Administration

*Sponsored by the SNMMI Therapy Center of Excellence*

Organizers: Daniel Lee, MD; Yoram Baum, MD
Moderators: Daniel Lee, MD; Tina Buehner, PhD, CNMT, FSNMMI-TS

**Session Description**

This is a practical session on the administration of therapeutic radiopharmaceuticals including 2 talks on techniques for intravenous administration (gravity and pump methods), a talk on acute/subacute complications of extravasations and a talk on room preparation, containing and addressing spills and contamination events, and patient education/radiation safety precautions

**Session Objectives**

1. Describe two methods of intravenous administration of radiopharmaceuticals
2. Recognize acute/subacute complications of radiopharmaceutical extravasation
3. Address spills and contamination events, as well as radiation safety precautions

**Presentations Include:**

- Techniques of IV Therapy Administration -The Gravity Method  
  Miranda Womack
- Techniques of IV Therapy Administration – The Pump Method  
  James Crowley, MHA, CNMT
- IV Therapy Administration: What Can Go Wrong? Acute and Subacute Complications of Extravasations  
  Ila Sethi, MD
- Radiation Safety Aspects in IV Therapy Administration  
  Monica Johnson
- Q&A

**SATURDAY, JANUARY 30**

11:45 am–1:15 pm ET

Prostate Cancer PSMA Therapy

*Sponsored by the SNMMI Therapy Center of Excellence*

Organizers: Ephraim E. Parent, MD, PhD; Daniel Lee, MD
Moderators: Ephraim E. Parent, MD

**Session Description**

Multi-disciplinary discussion regarding PSMA therapy and its role regarding other hormonal and chemotherapeutic agents. Practical considerations regarding patient selection and administration will be discussed.

**Session Objectives**

1. Describe the role of PSMA radiotherapy for prostate cancer
2. Determine identification of ideal candidates for PSMA therapy
3. Recognize practical considerations for PSMA radiotherapy administration

**Presentations Include:**

- Medical Management of Prostate Cancer and the Role of PSMA Radiotherapy  
  A. Oliver Sartor, MD
- Patient Selection and Management of PSMA Therapy  
  Phillip Kuo, MD, PhD
- Practical Considerations of PSMA Radiotherapy Administration  
  Ayse Tuba Kendi, MD
- Q&A
The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

**SATURDAY, JANUARY 30**

2:15–3:45 pm ET

Updates on Radionuclide Therapies in Pediatrics: Current Status and Novel Applications

*Sponsored by the SNMMI Therapy Center of Excellence and the SNMMI Pediatric Imaging Council*

Organizers: Neeta Pandit-Taskar, MD; Victor Seghers, MD, PhD; Steve Y. Cho, MD

Moderators: Neeta Pandit-Taskar, MD; Victor Seghers, MD

**Session Description**

This session will provide an overview the status of MIBG therapy and explore the role of PRRT in pediatric patients. Clinical experience and trials data will be reviewed. Novel radionuclide therapy approaches, and techniques will be discussed.

**Session Objectives**
1. Examine the clinical indication, use and administration of MIBG therapy
2. Discuss the role of PRRT in neuroblastoma
3. Recognize novel targeting agents for treatment of pediatric tumors

**Presentations Include:**
- The Role of PRRT in NB
  *Jennifer E. Gains, MD*
- Thyroid Cancer – ATA Guidelines and Case Discussion
  *Adina L. Alazraki, MD*
- Novel Agents and Approaches for Treating Pediatric Tumors
  *Neeta Pandit-Taskar, MD*
- MIBG Therapies in NB
  *Susan E. Sharp, MD*
- Q&A

**SATURDAY, JANUARY 30**

4:15–5:45 pm ET

Updates and Clinical Applications of PRRT for NET

*Sponsored by the SNMMI Therapy Center of Excellence*

Organizers: Neeta Pandit-Taskar, MD; Steve Y. Cho, MD

Moderators: Steve Y. Cho, MD; Neeta Pandit-Taskar, MD

**Session Description**

This session will overview specific topic discussions in molecular imaging and peptide receptor radionigand therapy (PRRT) for neuroendocrine tumors (NET), including gastroenteropancreatic (GEP), pheochromocytomas and paragangliomas. We will review current practice, case discussions and novel emerging approaches.

**Session Objectives**
1. List the basic principles of PRRT and its oncologic applications in NET
2. Define the current indications, contraindications, and response assessments for PRRT in GEP
3. Examine emerging PRRT applications in pheochromocytoma and paraganglioma

**Presentations Include:**
- Clinical Oncology Diagnosis and Treatments for NET
  *Jennifer R. Eads, MD*
- Current and Emerging Molecular Imaging and PRRT for NET
  *Grace Kong, MD*
- Current and Emerging Molecular Imaging for PRRT for Pheochromocytoma and Paraganglioma
  *Frank Lin, MD*
- Case Series on PRRT in NET (Interactive SAM Session)
  *Steve Y. Cho, MD*
- Q&A
The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

Saturday, January 30

6:00–7:30 pm ET

Radioiodine Therapy for Differentiated Thyroid Cancer

Sponsored by the SNMMI Therapy Center of Excellence

Organizer/Moderator: Frederick D. Grant, MD

Session Description

Although radioiodine (I-131) therapy for thyroid cancer has been one of the mainstays of nuclear medicine practice for decades, the indications and perceived utility of this therapy continue to evolve. Speakers in this session will review the current use of radioiodine therapy from the perspective of a clinical endocrinologist, present an approach to radioiodine therapy from the perspective of a nuclear medicine physician, and discuss current thinking regarding the potential risks and late effects of radioiodine therapy.

Session Objectives

1. Discuss the evolving endocrinology perspective on the use of radioiodine therapy for differentiated thyroid cancer.
2. Describe the use of radioiodine (I-131) for the treatment of differentiated thyroid cancer.
3. Summarize potential risks and late effects of radioiodine (I-131) therapy.

Presentations Include:

- The Clinical Endocrinologist’s Evolving Perspective on the Use of Radioactive Iodine for Differentiated Thyroid Carcinoma
  Erik K. Alexander, MD

- Radioiodine (I-131) Treatment of Differentiated Thyroid Cancer: The Nuclear Medicine Perspective
  Robert Flavell, MD, PhD

- Potential Risks and Late Effects of Radioiodine (I-131) Therapy
  Bennett S. Greenspan, MD, FACNM, FACR, FSNMMI

- Q&A
The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI’s specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

**SUNDAY, JANUARY 31**

**8:45–9:45 am ET**

**Special Session: SNMMI Inclusion Task Force Update**

Details to come.

**SUNDAY, JANUARY 31**

**10:00–11:30 am ET**

**Hot Topics in Nuclear Cardiology 2020: Case-Based Review**

*Sponsored by the SNMMI Cardiovascular Council*

Organizer: Edward J. Miller, MD, PhD
Moderator: Brett W. Sperry, MD; Marie A. Gueratty, MD, PhD

**Session Description**

Nuclear cardiology has evolved rapidly. Practitioners need to be familiar with new tracers, disease processes, and technology. This clinically oriented session for nuclear cardiology readers will utilize a practical, case-based review strategy for interpreting Tc99m PYP imaging for cardiac amyloidosis, FDG-PET for cardiac sarcoidosis, CZT and SPECT/CT cases and artifacts, and myocardial blood flow quantification from cardiac PET.

**Session Objectives**

1. Discuss the optimal methods to acquire and interpret Tc99m PYP imaging for cardiac amyloidosis, including artifacts
2. Gain expertise in the use of hybrid imaging systems and optimal approaches for the interpretation of FDG-PET for cardiac sarcoidosis
3. Develop understanding of artifacts specific to dedicated cardiac CZT SPECT c cameras and SPECT/CT c cameras in the interpretation of nuclear cardiology studies
4. Examine practical applications and pitfalls in the interpretation and reporting of myocardial blood flow quantification from PET

**Presentations Include:**

- Optimal Performance and Interpretation of Tc99m PYP Imaging for Cardiac amyloidosis: Perils, Pearls, and Pitfalls
  
  *Shivda Pandey, MD*

- The Use of Hybrid PET/CT Imaging in the Interpretation of FDG PET for Cardiac Sarcoidosis
  
  *Edward J. Miller, MD, PhD*

- How to Interpret and Integrate PET Myocardial Blood Flow into Clinical Reporting and Practice
  
  *Timothy Bateman, MD*

- Q&A

**SUNDAY, JANUARY 31**

**11:45 am–1:15 pm ET**

**COVID-19: Effects on Clinical Care and Education**

*Sponsored by the SNMMI Academic Council; SNMMI General Clinical Nuclear Medicine Council*

Organizers: Twyla Bartel, DO, MBA, FACNM; Lionel Zuckier, MD, MBA, FRCPC
Moderators: Erica Cohen, DO, FACNM; Lionel Zuckier, MD, MBA, FRCPC

**Session Description**

The COVID-19 pandemic has affected nearly all aspects of medicine. It has affected how we teach and learn via social distancing. It has also changed the physical layout of our departments, the way we interact with patients, colleagues, and trainees, and even the way we do some examinations. In addition, as a new disease, COVID-19 results in several new clinical manifestations that may be noted on nuclear medicine examinations.

The course will begin with a review of alternative and/or the best teaching methods for learning and retention, especially those that can be adapted to a remote situation, and followed by a discussion of data collected on which teaching methods have had the most positive impact during this COVID-19. We will then review multiple clinical aspects of the COVID-19 pandemic, in terms of its effects on medical care and “clinical” knowledge, and the business of medicine. We hope to present both best practices regarding COVID-19 and up-to-date clinical information. This should be of value to nuclear medicine technologists, trainees and
practicing physicians, both in primarily educational and non-educational settings.

**Session Objectives**
1. Review and explain different teaching methods and which work best for learning retention.
2. Discuss data gathered on teaching methods during COVID which have had a positive impact on learning while physically distancing.
3. Ensure the safe practice of nuclear medicine.
4. Recognize findings on nuclear medicine studies in patients affected by COVID-19.

**Presentations Include:**
- **Best Evidence-Based Teaching Methods for Learning Retention and which Can Work Well Remotely**
  Twyla Bartel, DO, MBA, FACNM
- **What Our Data Analysis Shows on Which Methods During COVID Have Most had a Positive Impact on Learning**
  Shana Elman, MD
- **Effect of COVID-19 on Nuclear Medicine Operations Including Cardiovascular Manifestations**
  Vasken Dilsizian, MD, FSNMMI
- **Non-Cardiac Manifestation of COVID-19 in the Nuclear Medicine Suite Including Safe Pulmonary Scintigraphy**
  Lionel Zuckier, MD, MBA, FRCPC
- Q&A

**SUNDAY, JANUARY 31**

2:15–3:45 pm ET

**Artificial Intelligence in Nuclear Medicine**

_Sponsored by the SNMMI Physics, Instrumentation and Data Sciences Council_

Organizer: Joyita Dutta

**Session Description**
This session will focus on the fundamentals of artificial intelligence (AI) and highlight recent advances in deep learning in the context of nuclear medicine imaging. Deep learning is particularly well-suited for the analysis of large and complex datasets including images. Unlike classical machine learning approaches, which rely on predetermined handcrafted features, deep learning algorithms learn features that are most meaningful for a given task. In this session, we aim to provide both a foundational overview of AI methodology and discuss major applications of AI in nuclear medicine. The session is intended to provide the attendees with an in-depth understanding of AI tools that have the potential to significantly improve diagnosis, prognosis, and treatment response assessment, and to take a significant step toward realization of precision (personalized) medicine.

**Session Objectives**
1. Describe the framework of a deep learning algorithm and how this differs from classical machine learning.
2. Examine motivations for applying machine learning and deep learning methods to radiological images, and how these may significantly improve diagnosis, prognosis, and treatment response assessment.
3. Recognize the pitfalls and challenges of, as well as solutions towards, the translation of deep learning methods to routine clinical practice.

**SUNDAY, JANUARY 31**

4:15–5:45 pm ET

**Molecular Brain Imaging and the ATN Framework**

_Sponsored by the SNMMI Brain Imaging Council_

Organizer/Moderator: Karina Mosci, MD

**Session Description**
Dementia is multifactorial and presents a challenge both for diagnosis and treatment. The purpose of the session is to review the paper of Molecular Imaging in the NIA-AA research framework that defines AD biologically, by neuropathologic change or biomarkers, and treats cognitive impairment as a symptom/sign of the disease rather than the definition of the disease. The session will address ATN concepts while reviewing the actual clinical applications for amyloid, Tau and FDG PET in brain imaging. The session aims to improve the skills of training and already trained professionals.

**Session Objectives**
1. Examine the concept of ATN framework
2. Interpret amyloid, Tau and FDG-PET in AD
3. Discuss the potential of Molecular Imaging for personalized medicine by coding pathologic change
GENERAL NUCLEAR MEDICINE TRACK

The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI’s specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

Presentations Include:
- Amyloid PET
  Jonathan McConathy, MD, PhD
- Tau PET
  Victor Villenmagne, MD
- Neurodegeneration/ FDG-PET
  Satoshi Minoshima, MD, PhD
- Q&A

▶ SUNDAY, JANUARY 31

6:00–7:30 pm ET

Pediatric Nuclear Medicine Applications:
Common to Obscure

Sponsored by the SNMMI Pediatric Imaging Council

Organizers: Victor Seghers, MD, PhD
Moderators: Victor Seghers, MD, PhD; Reza Vali, MD

Session Description
This session will cover basic clinical pediatric nuclear medicine techniques in the areas of GU-Cystography, GI, and Epilepsy. It will also cover more obscure clinical examinations such as Lymphangiography and CSF-scintigraphy. The intended audience is general nuclear medicine physicians and technologist who are interested in or perform some pediatric cases. This course supports general “Nuts and Bolts” themes and are targeted for typical attendees of Mid-Winter Meetings.

Session Objectives
1. Discuss common pediatric nuclear medicine applications
2. Gain insight into less common nuclear medicine applications
3. Learn about best practices (technique, imaging protocol, radiation dose) of various pediatric nuclear medicine exams

Presentations Include:
- Pediatric GU Cystography
  Tejal Mody, MD
- Pediatric GI Applications in Nuclear Medicine
  Zvi Bar-Sever, MD
- Pediatric Epilepsy: Interesting Cases
  Neha Kwatra, MD
- Pediatric Lymphangiography
  Marguerite T. Parisi, MD, MS Ed
- Pediatric CSF-Scintigraphy
  Hedieh Khalatbari, MD
- Q&A
SATELLITE SYMPOSIA

Hear directly from industry in these popular one-hour virtual presentations. Pre-registration is not required but encouraged to receive any pre-meeting materials from the organizing company.

**Precision Imaging for Detection and Localization of Recurrent Prostate Cancer**

**FRIDAY, JANUARY 29  ▶️  1:15–2:15 PM ET**

*Sponsored by Blue Earth Diagnostics, Inc.*

**Speaker:** Munir Ghesani, MD, FACNM, FACR; Chief of Nuclear Medicine, Mount Sinai Health, NY

**Session Objectives**
1. Understand the prevalence, incidence, and mortality rates associated with prostate cancer
2. Demonstrate the challenges of detecting and localizing recurrent prostate cancer using standard imaging techniques
3. Examine the diagnostic performance and value of PET/CT in detecting and localizing recurrent prostate cancer to inform clinical management plans
4. Evaluate PET/CT in clinical practice by reviewing case studies

**Role of Cerianna™ (18F Fluoroestradiol) in Breast Cancer imaging**

**FRIDAY, JANUARY 29  ▶️  1:15–2:15 PM ET**

*Sponsored by Zionexa*

**Speakers:**
- Dr. Robert S. Bridwell, MD, MBA, Charles Town, West-Virginia
- Dr. Hannah M. Linden, MD, Seattle Cancer Care Alliance, Washington
- Dr. Deepak Behera, MD, San Francisco, California

Dr. Bridwell reviews Cerianna’s use in clinical scenarios including some case studies. Dr. Linden and Dr Behera will have a discussion on the oncologist point of view on impact of 18F Fluoroestradiol in breast cancer management. The session will conclude with a Q&A session with the speakers.

**Detectnet™ (copper Cu 64 dotatate injection) – A Novel Agent for PET Imaging of Neuroendocrine Tumors**

**SATURDAY, JANUARY 30  ▶️  1:15–2:15 PM ET**

*Sponsored by Curium*

**Speakers:**
- Erik Mittra, MD, PhD – Chief, Nuclear Medicine & Molecular Imaging – Oregon Health & Science University (OHSU)
- Adam Brown, BS, NMTCB (CNMT)(CT)(PET), RT(N) – Manager, Nuclear Medicine & Molecular Imaging – OHSU

Dr. Erik Mittra will present a summary of the clinical data on the use of Detectnet (copper Cu 64 dotatate injection) in Neuroendocrine Tumors (NETs), including case studies highlighting the clinical utility in various scenarios. Mr. Adam Brown will be discussing the protocol and image acquisition details. The session will conclude with a panel Q&A session, including the speakers as well as Dr. Eric Liu, a general surgeon specializing in NET patient care at the Rocky Mountain Cancer Center.
Expanding SPECT/CT Integration into Clinical Nuclear Medicine  
**SUNDAY, JANUARY 31  ▶  1:15–2:15 PM ET**  
*Sponsored by Siemens Healthineers*

**Speaker:** Kathryn A. Morton, MD, Professor, Department of Radiology and Imaging Sciences. Chief, Nuclear Medicine Service University of Utah School of Medicine

The availability of high-quality SPECT/CT has greatly expanded the diagnostic value of nuclear medicine and has provided opportunities for improved therapeutic planning. SPECT/CT can be applied to almost any nuclear medicine imaging study with a resultant improvement in definitive interpretative assessment and precise anatomic relevance. The goal of the symposium is to comprehensively profile the current and potential role of SPECT/CT for many nuclear medicine applications, including those where SPECT/CT has not played a traditional role. Join us Sunday as Dr. Morton reviews her experiences using SPECT/CT in a clinically expanded role.

---

**Ga-68 PSMA-11: Advances in Technology, Demand & Supply | Industry Leaders’ Round-Table Discussion**  
**SUNDAY, JANUARY 31  ▶  1:15–2:15 PM ET**  
*Sponsored by Telix Pharmaceuticals*

**Speakers:**
- Chris Behrenbruch, CEO, Telix Pharmaceuticals (Moderator)
- Delphine Chen, MD, Director of Molecular Imaging Seattle Cancer Care Alliance University of Washington
- Jean Bonnet, Head of Strategy, Sales & Marketing, IRE
- Uno Zetterberg, Global Sales & Product Director, Cyclotrons & PET Radiopharmacy, GE Healthcare
- Serge Lyashchenko, PharmD, MSKCC

This Symposium offers perspectives from Industry Leaders on recent advances in PSMA-PET Imaging and how the radiopharmaceutical industry will meet the ever increasing demand for Ga-68 PSMA-11. Topics will include insight into isotope production, distribution and supply chain, as well as the practical impact on physician practice.
VIRTUAL EXHIBIT HALL

Meet with top companies at the 2021 SNMMI Mid-Winter and ACNM Annual Meeting and explore the latest technologies and products available in the field.

CURRENT EXHIBITING COMPANIES INCLUDE:

**Advanced Accelerator Applications**
8205 B&G Court
Stokesdale, NC 27357
Phone: 336.643.2000
www.ais-nuclear.com

**American Board of Nuclear Medicine (ABNM)**
1030 Highlands Plaza Drive, Suite 511E
St. Louis, MO 63110
314.367.2225
www.abnm.org

**American College of Radiology (ACR)**
1891 Preston White Drive
Reston, VA 20191
Phone: 800.227.5463
www.acr.org

**American Society of Nuclear Cardiology (ASNC)**
9302 Lee Highway
Suite 1210
Fairfax, Virginia 22031
Phone: 703.459.2555
www.asnc.org

**Blue Earth Diagnostics**
25 Mall Road, Suite 206
Burlington, MA 01803
Phone: 781.494.4100
www.blueearthdiagnostics.com

**Bracco Diagnostics Inc.**
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831
Phone: 609.514.2200
https://cardiogen.com/

**Cardinal Health**
7200 Cardinal Place
Dublin, OH 43017
Phone: 614.757.5000
www.cardinalhealth.com

**Curium**
111 West Port Plaza, Suite 800
St. Louis, MO 63146
www.curiumpharma.com

**Hermes Medical Solutions**
710 Cromwell Drive, Suite A
Greenville, NC 27858
Phone: 252.751.0664
www.hermesmedical.com

**IBA SA**
Chemin du Cyclotron, 3
1348 Louvain la Neuve
Belgium
Phone: 0032 10 201 275
www.iba-radiopharmasolutions.com

**Intersocietal Accreditation Commission (IAC)**
6021 University Blvd.
Suite 500
Ellicott City, MD 21043
Phone: 800.838.2110
www.intersocietal.org

**ITM Isotopen Technologien Munchen AG**
Walther von Dyck Strasse 4
Garching, Bavaria 85748
Germany
Phone: +49 89 3298986-155
www.itm.ag

**Jubilant Radiopharma**
16751 Transcanada Highway
Kirkland QC H9H 4J4
Canada
Phone: 514.694.8220
www.jubilantradiopharma.com

As of January 11, 2021
VIRTUAL EXHIBIT HALL

Meet with top companies at the 2021 SNMMI Mid-Winter and ACNM Annual Meeting and explore the latest technologies and products available in the field.

CURRENT EXHIBITING COMPANIES INCLUDE:

Lantheus Holdings
331 Treble Cove Road
North Billerica, MA 01862
Phone: 800.362.2668
www.lantheus.com

MedImage, Inc.
331 Metty Drive
Suite 1
Ann Arbor, MI 48103
Phone: 734.665.5400 *121
www.medimage.com

MIM Software Inc.
25800 Science Park Drive,
Suite 180
Cleveland, OH 44122
Phone: 216.455.0600
www.mimsoftware.com

NorthStar Medical Radioisotopes, LLC
1800 Gateway Blvd.
Beloit, WI 53511
Phone: 608.313.8000
www.northstarnm.com

POINT Biopharma Inc.
4850 W 78th Street
Indianapolis, IN 46268
www.pointbiopharma.com

Siemens Medical Solutions USA
2501 North Barrington Road
Hoffman Estates, IL 60192
Phone: 847.304.7700

SOFIE Co.
21000 Atlantic Boulevard
Suite 730
Dulles, VA 20166
Phone: 703.787.7900
www.sofie.com

Spectrum Dynamics Medical
301 N. Cattleman Road,
Suite 109
Sarasota, FL 34232
Phone: 941.928.6922
www.spectrum-dynamics.com

Tema Sinergie S.p.A.
Via Malpighi 120
48018 Faenza (RA)
Italy
Phone: +39 0546 622663
www.temasinergie.com

TTG Imaging Solutions, LLC
2403 Sidney Street Suite 220
Pittsburgh, PA 15203
Phone: 866.682.6331
www.ttgimagingsolutions.com

Zionexa
10475 Crosspoint Boulevard
Suite 250
Indianapolis, IN 46256
Phone: 844.946.6392
www.zionexa.com

As of January 11, 2021
Women in Nuclear Medicine Movie Night

Radium Girls

Saturday, January 30
8:00PM (ET)

To attend, please visit the Networking Lounge in the meeting platform.
We would like to thank our 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting Sponsors:

► TITLE SPONSOR

[Logo of Advanced Accelerator Applications, A Novartis Company]

► GOLD SPONSOR

[Logo of Point Biopharma]

► BRONZE SPONSORS

[Bracco, Hermes Medical Solutions, ITM, MIM, Spectrum Dynamics Medical]

► SATELLITE SYMPOSIA SPONSORS

[Blue Earth Diagnostics, Curium Life Forward, Siemens Healthineers, Telix Pharmaceuticals, Zionexa]
A History of Innovation, A Future of Promise

TechneLite®
Technetium Tc 99m Generator

AZEDRA®
ioseguan 131 injection for intravenous use

QUADRAMET®
(Samarium SM 153 Lexidronam Injection)

NEUROLITE®
Kit for the Preparation of Technetium Tc99m BICISATE for Injection

Cardiolite®
Kit for the Preparation of Technetium Tc99m Sestamibi for Injection

Thallium
Thallous Chloride TI 201 Injection

Gallium
Gallium Citrate Ga 67 Injection

For more information on Lantheus Nuclear Products contact customer service 1-800-299-3431

For more information on AZEDRA contact the AZEDRA Service Connection® 1-844-293-3721

For full Prescribing Information on each of the Lantheus products, please visit www.lantheus.com
The ACR® is the most trusted resource for your nuclear medicine and PET accreditation. Visit us in the ACR virtual booth at the SNMMI Mid-Winter Meeting to learn how to maintain excellence in patient quality and safety through the ACR Nuclear Medicine and PET Accreditation Programs.

**Benefits of ACR Accreditation:**

- Complimentary, expedited review.
- Easy online application process.
- One application for all nuclear medicine modules.
- Imaging review by expert nuclear medicine physicians and medical physicists.

**Ask about the SNMMI meeting discount**

Save $100 off each modality (excluding mammography)